CTTI Project: Developing Novel Endpoints, Planning Decentralized Trials
Today the Clinical Trials Transformation Initiative (CTTI) announced a new online Digital Health Trials Hub featuring enhanced recommendations and additional resources.
Related: Developing Novel Endpoints
Obtaining Novel Endpoint Reliability and Acceptance Expert Meeting
JULY 27, 2021 TO JULY 28, 2021
CTTI Project: Developing Novel Endpoints
Meeting Objectives:
- Identify the barriers and discuss solutions to the adoption of DHT-derived endpoints into pivotal trials
- Discuss the data needed to prove that a DHT-derived endpoint is ready for a pivotal trial
- Explore how collaboration and other new efforts can advance the adoption of DHT-derived endpoints
Meeting Location:
Virtual Meeting
Meeting Materials:
Day 1
- Session I: DHT-Derived Novel Endpoint Development: Current Landscape
- Session II: DHT-Derived Endpoints in Trials: The Reality vs. the Idea
- Mentimeter Results - Day 1
Day 2
The views and opinions expressed in these presentations are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.
Next Steps for Obtaining Novel Endpoint Reliability & Acceptance
CTTI Project: Developing Novel Endpoints
Webinar Presenters:
- Michelle Crouthamel, AbbVie
- Jennifer Goldsack, DiMe
- Lindsay Kehoe, CTTI
- Alicia Staley, Medidata
Webinar Resources:
CTTI’s Digital Health Trials Hub: Revised Recommendations and New Resources for DCTs and Novel Endpoints
CTTI Project: Developing Novel Endpoints and Planning Decentralized Trials
Webinar Presenters:
- Megan Doyle, Amgen
- Jorg Goldhahn, ETH Zurich
- Phil Green, CTTI
- Lindsay Kehoe, CTTI
- Elizabeth Kunkoski, FDA
- Jeremy Wyatt, ActiGraph
- Reem Yunis, Medable